The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
ACADIA PHARMACEUTICALS INC | COM | 004225108 | 17,245,763 | 916,353 | SH | SOLE | 916,353 | 0 | 0 | ||
AFTERNEXT HEALTHTECH ACQUISITION CORP | *W EXP 99/99/999 | G01109126 | 61,087 | 366,666 | SH | SOLE | 366,666 | 0 | 0 | ||
AMICUS THERAPEUTICS INC | COM | 03152W109 | 16,193,341 | 1,460,175 | SH | SOLE | 1,460,175 | 0 | 0 | ||
APELLIS PHARMACEUTICALS INC | COM | 03753U106 | 18,712,192 | 283,690 | SH | SOLE | 283,690 | 0 | 0 | ||
ARES ACQUISITION CORP | *W EXP 02/02/202 | G33032122 | 444,141 | 504,706 | SH | SOLE | 504,706 | 0 | 0 | ||
ARVINAS INC | COM | 04335A105 | 13,449,636 | 492,300 | SH | SOLE | 492,300 | 0 | 0 | ||
ASCENDIS PHARMA A/S | SPONSORED ADR | 04351P101 | 16,734,040 | 156,072 | SH | SOLE | 156,072 | 0 | 0 | ||
BILANDER ACQUISITION CORP | *W EXP 05/19/202 | 09001T114 | 23,887 | 183,749 | SH | SOLE | 183,749 | 0 | 0 | ||
BRIDGETOWN HOLDINGS LTD | *W EXP 09/30/202 | G1355U121 | 134,429 | 895,000 | SH | SOLE | 895,000 | 0 | 0 | ||
CEREVEL THERAPEUTICS HLDNG I | COM | 15678U128 | 13,157,064 | 539,445 | SH | SOLE | 539,445 | 0 | 0 | ||
CHURCHILL CAPITAL CORP V | *W EXP 10/29/202 | 17144T115 | 114,322 | 612,000 | SH | SOLE | 612,000 | 0 | 0 | ||
CHURCHILL CAPITAL CORP VI | *W EXP 02/17/202 | 17143W119 | 59,400 | 540,000 | SH | SOLE | 540,000 | 0 | 0 | ||
CHURCHILL CAPITAL CORP VII | *W EXP 02/29/202 | 17144M110 | 67,130 | 548,000 | SH | SOLE | 548,000 | 0 | 0 | ||
COMPASS DIGITAL ACQUISITION CORP | *W EXP 09/29/202 | G2476C123 | 59,834 | 459,906 | SH | SOLE | 459,906 | 0 | 0 | ||
CONCORD ACQUISITION CORP II | *W EXP 99/99/999 | 20607U116 | 28,583 | 408,333 | SH | SOLE | 408,333 | 0 | 0 | ||
CONYERS PARK III ACQUISITION CORP | *W EXP 08/12/202 | 21289P110 | 114,333 | 571,666 | SH | SOLE | 571,666 | 0 | 0 | ||
CORSAIR PARTNERING CORP | *W EXP 07/06/202 | G2540H116 | 53,580 | 334,666 | SH | SOLE | 334,666 | 0 | 0 | ||
CRINETICS PHARMACEUTICALS IN | COM | 22663K107 | 13,946,938 | 868,427 | SH | SOLE | 868,427 | 0 | 0 | ||
CYTOKINETICS INC | COM NEW | 23282W605 | 14,561,376 | 413,793 | SH | SOLE | 413,793 | 0 | 0 | ||
FIRST LIGHT ACQUISITION GROUP INC | *W EXP 03/14/202 | 320703119 | 26,863 | 655,200 | SH | SOLE | 655,200 | 0 | 0 | ||
GALAPAGOS NV | SPON ADR | 36315X101 | 17,181,624 | 444,659 | SH | SOLE | 444,659 | 0 | 0 | ||
HOME PLATE ACQUISITION CORP | *W EXP 09/30/202 | 43734R111 | 218,730 | 690,000 | SH | SOLE | 690,000 | 0 | 0 | ||
IVERIC BIO INC | COM | 46583P102 | 17,605,188 | 723,600 | SH | SOLE | 723,600 | 0 | 0 | ||
JAWS HURRICANE ACQUISITION CORP | *W EXP 03/26/202 | 47201B111 | 60,062 | 387,249 | SH | SOLE | 387,249 | 0 | 0 | ||
MARBLEGATE ACQUISITION CORP | *W EXP 08/31/202 | 56608A113 | 110,177 | 735,000 | SH | SOLE | 735,000 | 0 | 0 | ||
PROTHENA CORP PLC | SHS | G72800108 | 16,072,652 | 331,600 | SH | SOLE | 331,600 | 0 | 0 | ||
RELAY THERAPEUTICS INC | COM | 75943R102 | 13,938,067 | 846,270 | SH | SOLE | 846,270 | 0 | 0 | ||
ROSS ACQUISITION CORP II | *W EXP 02/01/202 | G7641C114 | 115,192 | 439,666 | SH | SOLE | 439,666 | 0 | 0 | ||
SAGE THERAPEUTICS INC | COM | 78667J108 | 16,316,775 | 388,865 | SH | SOLE | 388,865 | 0 | 0 | ||
SAREPTA THERAPEUTICS INC | COM | 803607100 | 16,919,597 | 122,757 | SH | SOLE | 122,757 | 0 | 0 | ||
SENIOR CONNECT ACQUISITION COR | *W EXP 12/31/202 | 81723H116 | 51,308 | 1,014,000 | SH | SOLE | 1,014,000 | 0 | 0 | ||
SKYDECK ACQUISITION CORP | *W EXP 05/13/202 | G82220115 | 18,088 | 361,756 | SH | SOLE | 361,756 | 0 | 0 | ||
SOLID BIOSCIENCES INC | COM NEW | 83422E204 | 2,317,182 | 488,857 | SH | SOLE | 488,857 | 0 | 0 | ||
SPRINGWORKS THERAPEUTICS INC | COM | 85205L107 | 15,810,306 | 614,231 | SH | SOLE | 614,231 | 0 | 0 | ||
SWIFTMERGE ACQUISITION CORP | *W EXP 12/13/202 | G63836111 | 59,878 | 490,000 | SH | SOLE | 490,000 | 0 | 0 | ||
TRAVERE THERAPEUTICS INC | COM | 89422G107 | 19,683,720 | 875,221 | SH | SOLE | 875,221 | 0 | 0 | ||
YS BIOPHARMA CO LTD | *W EXP 03/15/202 | G9845F117 | 76,293 | 489,999 | SH | SOLE | 489,999 | 0 | 0 | ||
ZIMMER ENERGY TRANSITION ACQUISITION CORP | *W EXP 06/16/202 | 989570114 | 60,118 | 358,270 | SH | SOLE | 358,270 | 0 | 0 |